Amneal Pharmaceuticals, Inc.

Other than as set forth below, there have been no material changes to the disclosures presented in our 2025 Annual Report on Form 10-K under Item 1A. Risk Factors.

Risks Related to our Pending Acquisition of Kashiv BioSciences, LLC (“Kashiv”)

The pending acquisition of Kashiv may not be completed as currently contemplated, and we and our stockholders may not realize the anticipated benefits therefrom.

As previously disclosed, on April 21, 2026, we entered into a Membership Interest Purchase Agreement to acquire 100% of the outstanding membership interests of Kashiv (the “Acquisition”). The consummation of the Acquisition is subject to the satisfaction or waiver of certain conditions not necessarily within our control, including stockholder and regulatory approvals, and it is possible that such conditions may prevent or delay or otherwise materially adversely affect our ability to complete the Acquisition, which in turn could negatively impact us and our growth prospects. Neither we nor Kashiv can provide assurance that the conditions to completing the Acquisition will be satisfied or waived and, accordingly, that the Acquisition will be completed on the timeline that the parties anticipate, on the terms and conditions that the parties anticipate, or at all. In addition, the anticipated benefits of the acquisition may not be realized on the expected scale or timeline.